Anti-c-Kit/CD117 Antibody (SR-1)
Based on 1 Customer Validation
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- Molecular Weight:146.12 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Mouse IgG2a kappa
Human
c-Kit/CD117
Anti-c-Kit/CD117 Antibody (SR-1) (10 μg/mL, 12 h) inhibits cell growth and reduces cell-surface KIT expression in GIST48/GIST430/GIST882 cells[1].
Anti-c-Kit/CD117 Antibody (SR-1) (10 μg/mL, 2 h) allows for phagocytosis of gastrointestinal stromal tumor (GIST) cells by macrophages in GIST48/GIST430/GIST882 and LMS05 cells co-cultures[1].
Anti-c-Kit/CD117 Antibody (SR-1) (0.01-100 μg/mL, 2 weeks) inhibits cells proliferation in human hematopoietic stem cells (HSC)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-c-Kit/CD117 Antibody (SR-1) (500 μg, i.v., at days 1, 3, 5, and 7) depletes normal and myelodysplastic syndrome human hematopoietic stem cells (HSC) in HSC xenografted NSG mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:GIST430 xenograft tumor mice models of imatinib (HY-15463)-resistant and GIST882 xenograft tumor mice models of imatinib-sensitive (4-8 weeks, NSG mice)[1]
-
Dosage:500 μg
-
Administration:Intraperitoneally injection, weekly 2 weeks after cells engraftment
-
Result:Inhibited tumor growth.
-
Animal Model:Human hematopoietic stem cells (HSC)-xenografted NSG mice (prenatal day 0 (P0) to P3 newborn pups) [2]
-
Dosage:500 μg
-
Administration:Intravenously injection, at days 1, 3, 5, and 7
-
Result:Depleted human CD451CD13/331 cells.
Depleted cells from high and low-risk MDS subtypes.
Generated human myeloid and lymphoid cells in the BM.
Allowed subsequent engraftment of healthy human HSCs and restored of normal human hematopoiesis.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
in vivo c-Kit+ cell depletionin vitro c-Kit targetingImmunohistochemistry (frozen)
-
Immobilized KIT-D1-D3-His can bind Anti-c-Kit/CD117 Antibody (SR-1). The EC50 for this effect is 42.8 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 146.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-c-Kit/CD117 Antibody (SR-1)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Edris B, et al. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. [Content Brief]
[2]. Pang WW, et al. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood. 2019 May 9;133(19):2069-2078. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)